BACKGROUND: Normal metabolism generates several volatile organic compounds (VOCs) that are excreted in the breath (e.g. alkanes). In patients with lung cancer, induction of high-risk cytochrome p450 genotypes may accelerate catabolism of these VOCs, so that their altered abundance in breath may provide biomarkers of lung cancer. METHODS: VOCs in 1.0 L alveolar breath were analyzed in 193 subjects with primary lung cancer and 211 controls with a negative chest CT. Subjects were randomly assigned to a training set or to a prediction set in a 2:1 split. A fuzzy logic model of breath biomarkers of lung cancer was constructed in the training set and then tested in subjects in the prediction set by generating their typicality scores for lung cancer. RESULTS: Mean typicality scores employing a 16 VOC model were significantly higher in lung cancer patients than in the control group (p<0.0001 in all TNM stages). The model predicted primary lung cancer with 84.6% sensitivity, 80.0% specificity, and 0.88 area under curve (AUC) of the receiver operating characteristic (ROC) curve. Predictive accuracy was similar in TNM stages 1 through 4, and was not affected by current or former tobacco smoking. The predictive model achieved near-maximal performance with six breath VOCs, and was progressively degraded by random classifiers. Predictions with fuzzy logic were consistently superior to multilinear analysis. If applied to a population with 2% prevalence of lung cancer, a screening breath test would have a negative predictive value of 0.985 and a positive predictive value of 0.163 (true positive rate =0.277, false positive rate =0.029). CONCLUSIONS: A two-minute breath test predicted lung cancer with accuracy comparable to screening CT of chest. The accuracy of the test was not affected by TNM stage of disease or tobacco smoking. Alterations in breath VOCs in lung cancer were consistent with a non-linear pathophysiologic process, such as an off-on switch controlling high-risk cytochrome p450 activity. Further research is needed to determine if detection of lung cancer with this test will reduce mortality.
BACKGROUND: Normal metabolism generates several volatile organic compounds (VOCs) that are excreted in the breath (e.g. alkanes). In patients with lung cancer, induction of high-risk cytochrome p450 genotypes may accelerate catabolism of these VOCs, so that their altered abundance in breath may provide biomarkers of lung cancer. METHODS: VOCs in 1.0 L alveolar breath were analyzed in 193 subjects with primary lung cancer and 211 controls with a negative chest CT. Subjects were randomly assigned to a training set or to a prediction set in a 2:1 split. A fuzzy logic model of breath biomarkers of lung cancer was constructed in the training set and then tested in subjects in the prediction set by generating their typicality scores for lung cancer. RESULTS: Mean typicality scores employing a 16 VOC model were significantly higher in lung cancerpatients than in the control group (p<0.0001 in all TNM stages). The model predicted primary lung cancer with 84.6% sensitivity, 80.0% specificity, and 0.88 area under curve (AUC) of the receiver operating characteristic (ROC) curve. Predictive accuracy was similar in TNM stages 1 through 4, and was not affected by current or former tobacco smoking. The predictive model achieved near-maximal performance with six breath VOCs, and was progressively degraded by random classifiers. Predictions with fuzzy logic were consistently superior to multilinear analysis. If applied to a population with 2% prevalence of lung cancer, a screening breath test would have a negative predictive value of 0.985 and a positive predictive value of 0.163 (true positive rate =0.277, false positive rate =0.029). CONCLUSIONS: A two-minute breath test predicted lung cancer with accuracy comparable to screening CT of chest. The accuracy of the test was not affected by TNM stage of disease or tobacco smoking. Alterations in breath VOCs in lung cancer were consistent with a non-linear pathophysiologic process, such as an off-on switch controlling high-risk cytochrome p450 activity. Further research is needed to determine if detection of lung cancer with this test will reduce mortality.
Authors: Peter J Mazzone; Xiao-Feng Wang; Yaomin Xu; Tarek Mekhail; Mary C Beukemann; Jie Na; Jonathan W Kemling; Kenneth S Suslick; Madhu Sasidhar Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: C Brunner; W Szymczak; W Li; C Hoeschen; S Mörtl; F Eckardt-Schupp; U Oeh Journal: Radiat Environ Biophys Date: 2010-09-04 Impact factor: 1.925
Authors: Alexander A Aksenov; Konstantin O Zamuruyev; Alberto Pasamontes; Joshua F Brown; Michael Schivo; Soraya Foutouhi; Bart C Weimer; Nicholas J Kenyon; Cristina E Davis Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2017-06-27 Impact factor: 3.205
Authors: Amel Bajtarevic; Clemens Ager; Martin Pienz; Martin Klieber; Konrad Schwarz; Magdalena Ligor; Tomasz Ligor; Wojciech Filipiak; Hubert Denz; Michael Fiegl; Wolfgang Hilbe; Wolfgang Weiss; Peter Lukas; Herbert Jamnig; Martin Hackl; Alfred Haidenberger; Bogusław Buszewski; Wolfram Miekisch; Jochen Schubert; Anton Amann Journal: BMC Cancer Date: 2009-09-29 Impact factor: 4.430
Authors: Tatjana Abaffy; Robert Duncan; Daniel D Riemer; Olaf Tietje; George Elgart; Clara Milikowski; R Anthony DeFazio Journal: PLoS One Date: 2010-11-04 Impact factor: 3.240
Authors: Wojciech Filipiak; Andreas Sponring; Tomas Mikoviny; Clemens Ager; Jochen Schubert; Wolfram Miekisch; Anton Amann; Jakob Troppmair Journal: Cancer Cell Int Date: 2008-11-24 Impact factor: 5.722